Novartis | Eiendeler

Assets Endring Dato
AbbVie USD 148.87B 12.65B 2024-03
Alcon AG USD 29.56B 49M 2024-03
Almirall EUR 2.31B 67.78M 2024-03
Amgen USD 92.98B 4.17B 2024-03
AstraZeneca USD 102.29B 1.17B 2024-03
Bayer EUR 119.88B 3.62B 2024-03
Biogen USD 26.57B 277.2M 2024-03
Bristol-Myers Squibb USD 99.03B 7.77B 2024-03
Eli Lilly USD 63.94B 6.03B 2024-03
Fresenius EUR 44.28B 1B 2024-03
Fresenius Medical Care EUR 34.34B 1.3B 2024-03
Galapagos EUR 4.36B 3.98M 2024-03
Genmab DKK 36.68B 1.39B 2024-03
Gilead Sciences USD 56.29B 5.83B 2024-03
GlaxoSmithKline GBP 58.51B 494M 2024-03
GRIFOLS EUR 21.44B 623.44M 2023-12
Hikma Pharmaceutical USD 4.68B 61M 2023-12
J&J USD 171.97B 5.9B 2024-03
Lonza CHF 16.85B 824M 2023-12
Merck EUR 49.5B 1.01B 2024-03
Merck USD 105.85B 878M 2024-03
Novartis USD 94.33B 5.61B 2024-03
Novartis USD 94.33B 5.61B 2024-03
Orion EUR 1.46B 22.2M 2024-03
Pfizer USD 221.1B 6.07B 2024-03
Philips EUR 29.41B 100M 2023-12
Recordati EUR 4.28B 49.78M 2024-03
Regeneron Pharmaceuticals USD 34.37B 1.29B 2024-03
Roche Holding CHF 90.47B 6.1B 2023-12
UCB EUR 15.54B 157M 2023-12



Novartis Eiendeler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Jun 2024.